Experts split into 2 teams and discussed the latest data, pressing questions, and clinical scenarios regarding CAR T-cell therapy in diffuse large B-cell lymphoma.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.